| Autor: |
Keenan RM; Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA., Miller WH, Lago MA, Ali FE, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Hwang SM, Jakas DR, Ku TW, Kwon C, Nguyen TT, Reader VA, Rieman DJ, Ross ST, Takata DT, Uzinskas IN, Yuan CC, Smith BR |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 1998 Nov 17; Vol. 8 (22), pp. 3165-70. |
| DOI: |
10.1016/s0960-894x(98)00555-1 |
| Abstrakt: |
In a 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists containing a benzimidazole as a novel arginine mimetic, we examined the effects of benzimidazole modifications and amide substitutions on both activity and pharmacokinetics. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect